Glucose-Responsive Insulin Nearing Human Clinical Trials
A few months ago we brought you news about a once a day insulin injection that was in the process of lab studies. It is now about to enter the human clinical studies.
The once a day injection is designed to maintain continuous control of a diabetics glucose levels. The continuous control will reduce the risk of a hypoglycemic incident (when the glucose level drops to low.)
Statement from Dr. Karin Hehenberger
"A measure of JDRF's (Juvenile Diabetes Research Foundation) success is identifying and advancing promising research that may benefit people with type 1 diabetes," says Dr. Karin Hehenberger, Senior Vice President of Strategic Alliances at JDRF. "Merck's acquisition of SmartCells is an example of exactly this. A potentially transformational innovation has now been taken up by a large pharmaceutical company thanks in part to our support. This acquisition adds important financial and drug development capabilities to this promising glucose-responsive insulin."
Type 1 diabetes affects nearly three million people in the United States alone. This once a day injection could be a life altering advancement for the children and adults who suffer from type 1 diabetes.
Source: Joana Casas / Juvenile Diabetes Research Foundation International